Full-Time
Updated on 12/20/2024
Develops cell therapy for chronic kidney disease
Junior, Mid
Winston-Salem, NC, USA
ProKidney focuses on treating Chronic Kidney Disease (CKD) through a novel cell therapy called rilparencel. This therapy aims to preserve kidney function in patients with advanced CKD, potentially delaying or eliminating the need for dialysis, which many patients currently rely on. ProKidney is in the late stages of clinical trials for rilparencel, and early results indicate it may effectively maintain kidney function. Unlike other treatments, ProKidney specifically targets CKD, a condition affecting over 35 million adults in the U.S., filling a significant gap in available therapies. The company's goal is to provide a new treatment option that improves the quality of life for CKD patients and reduces their reliance on dialysis.
Company Stage
IPO
Total Funding
$559.3M
Headquarters
Winston-Salem, North Carolina
Founded
2015
Help us improve and share your feedback! Did you find this helpful?